Press coverage about Allergan (NYSE:AGN) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Allergan earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.1665004744731 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2017 (finance.yahoo.com)
- Allergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego (finance.yahoo.com)
- William Meury Sells 58,879 Shares of Allergan plc (AGN) Stock (americanbankingnews.com)
- $3.36 Earnings Per Share Expected for Allergan plc (AGN) This Quarter (americanbankingnews.com)
- Allergan: Will Growth Come To A Screeching Halt? – Seeking Alpha (seekingalpha.com)
Several analysts have weighed in on AGN shares. Cowen set a $280.00 price objective on Allergan and gave the stock a “buy” rating in a report on Friday, October 20th. JPMorgan Chase & Co. set a $275.00 price objective on Allergan and gave the stock a “buy” rating in a report on Sunday, October 22nd. Zacks Investment Research raised Allergan from a “sell” rating to a “hold” rating in a report on Monday, October 23rd. Royal Bank of Canada set a $250.00 price target on Allergan and gave the company a “buy” rating in a research note on Sunday, October 29th. They noted that the move was a valuation call. Finally, Cantor Fitzgerald set a $231.00 price target on Allergan and gave the company a “hold” rating in a research note on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $227.23.
Allergan (NYSE:AGN) last posted its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.74 by $0.12. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The business had revenue of $4.33 billion during the quarter, compared to analysts’ expectations of $4.28 billion. During the same period in the prior year, the business earned $3.90 EPS. Allergan’s revenue for the quarter was up 12.0% compared to the same quarter last year. analysts anticipate that Allergan will post 15.57 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.76%. This is a boost from Allergan’s previous quarterly dividend of $0.70. The ex-dividend date is Tuesday, February 27th. Allergan’s dividend payout ratio is presently -23.35%.
In related news, insider William Meury sold 58,879 shares of the stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total transaction of $9,457,144.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Chris W. Bodine bought 3,030 shares of the stock in a transaction that occurred on Thursday, December 7th. The shares were acquired at an average cost of $164.77 per share, with a total value of $499,253.10. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 17,630 shares of company stock valued at $2,890,057. 0.36% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/02/17/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-allergan-agn-share-price.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.